Filing Overview
Cullinan Oncology, Inc. (now identified in the request metadata as Cullinan Therapeutics, Inc.) filed a Form 8-K dated February 28, 2022. The filing reports executive and director appointments and related compensation arrangements; it does not contain quarterly or annual financial statements.
Business and Corporate Developments
- Jeffrey Jones, M.D., MPH, MBA was appointed Chief Medical Officer effective February 28, 2022. He previously held senior global drug-development positions at Bristol Myers Squibb.
- Anne-Marie Martin, Ph.D. was appointed as a Class I director effective March 1, 2022. She has held senior translational medicine and experimental medicine roles at GlaxoSmithKline, Novartis, and Adaptimmune.
Compensation and Equity Arrangements
- Dr. Jones will receive an annual base salary of $460,000, a $100,000 sign-on bonus subject to prorated repayment in certain termination scenarios, and an annual incentive opportunity initially targeted at 40% of base salary.
- Dr. Jones received an option to purchase 215,000 shares at an exercise price of $14.34 per share, equal to the February 28, 2022 closing price. The option vests 25% on February 28, 2023, with the remainder vesting monthly over three years, subject to continued employment.
- Dr. Jones is eligible for severance of nine months of base salary, a prorated bonus, and certain COBRA support upon qualifying termination. Following a change in control, the arrangement provides for 12 months of base salary, the applicable target bonus, COBRA support, and accelerated vesting of unvested time-based equity awards.
- Dr. Martin received a director option with a grant-date fair value of $350,000 in lieu of the annual cash retainer. The award vests in equal one-third installments over three years, subject to continued service.
- Nonemployee directors are also eligible for annual options with a grant-date fair value of $150,000. These awards generally vest after one year and become fully exercisable upon a change in control.
Financial Metrics and Liquidity
The filing does not provide revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity measures, or financial guidance. It also does not present a comparable prior-period analysis.
Risks, Contingencies, and Unusual Items
- Compensation expense and potential dilution may result from the executive and director option grants.
- The employment agreement includes severance, benefit-continuation, change-in-control, and equity-acceleration obligations that could create contingent costs.
- The company entered into standard indemnification arrangements that may require reimbursement of certain legal expenses, judgments, fines, and settlements arising from service as an officer or director.
- Dr. Jones entered into confidentiality, assignment, nonsolicitation, and noncompetition obligations.
Key Facts for Investors to Verify
- Confirm the company’s current legal name and ticker following any subsequent corporate name change from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc.
- Review Exhibit 10.1 for the complete terms and definitions governing Dr. Jones’s severance, repayment obligations, change-in-control treatment, and equity award.
- Assess the accounting treatment, fair value, and dilution impact of the 215,000-share executive option and Dr. Martin’s director award.
- Review subsequent filings for changes in management, board composition, compensation, cash runway, financing needs, and clinical or regulatory developments.